Solid Biosciences Inc. (SLDB) has a negative trailing P/E of -4.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 54.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -23.09%, forward earnings yield 1.84%. PEG 0.08 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -20.2 | -0.08 | -5.16 | 0.00 | - |
| 2017 | -14.0 | -0.32 | -12.30 | 0.00 | - |
| 2018 | -11.9 | -0.31 | 7.12 | 0.00 | - |
| 2019 | -1.5 | -0.06 | 2.24 | 0.00 | - |
| 2020 | -4.5 | 0.11 | 2.98 | 0.00 | - |
| 2021 | -2.6 | 0.04 | 0.90 | 13.72 | - |
| 2022 | -0.5 | 1.35 | 0.22 | 5.66 | - |
| 2023 | -1.3 | 0.02 | 0.97 | 0.00 | - |
| 2024 | -1.3 | 0.04 | 1.19 | 0.00 | - |
| 2025 | -2.8 | 0.08 | 2.74 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-16.80 | $0.00 | $-21.54M | - |
| 2017 | $-24.26 | $0.00 | $-52.12M | - |
| 2018 | $-33.73 | $0.00 | $-74.8M | - |
| 2019 | $-43.05 | $0.00 | $-117.22M | - |
| 2020 | $-26.03 | $0.00 | $-88.29M | - |
| 2021 | $-10.13 | $13.62M | $-72.19M | -530% |
| 2022 | $-7.70 | $8.09M | $-65.51M | -809.4% |
| 2023 | $-4.83 | $0.00 | $-96.02M | - |
| 2024 | $-3.06 | $0.00 | $-124.7M | - |
| 2025 | $-1.99 | $0.00 | $-174.33M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.72 | $-2.17 – $-1.49 | $3.68M | $1.22M – $6.14M | 12 |
| 2027 | $-1.68 | $-1.94 – $-1.25 | $19M | $6.29M – $31.7M | 9 |
| 2028 | $-0.96 | $-1.56 – $-0.13 | $107M | $105.86M – $108.13M | 6 |
| 2029 | $0.15 | $0.02 – $0.29 | $279.56M | $92.56M – $466.5M | 4 |
| 2030 | $1.17 | $0.15 – $2.19 | $456.29M | $151.08M – $761.42M | 2 |
